Compositions and method for treating cardiovascular disease

Abstract

The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease in a subject having cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims.

What is claimed is:  
     
         1 . A method of treating cardiovascular disease in a subject having cardiovascular disease, the method comprising administering to the subject a therapeutically effective amount of an antagonist, wherein the antagonist is selected from the group consisting of an IL-17 antagonist, IL-18 antagonist, 4-1BB antagonist, CD30 antagonist and an OX40 antagonist.  
     
     
         2 . The method of  claim 1 , wherein the IL-17 antagonist is a soluble IL-17 receptor.  
     
     
         3 . The method of  claim 2 , wherein the soluble IL-17 receptor is a fusion protein.  
     
     
         4 . The method of  claim 1 , wherein the IL-17 antagonist is an antibody.  
     
     
         5 . The method of  claim 4 , wherein the antibody specifically binds the IL-17 receptor.  
     
     
         6 . The method of  claim 4 , wherein the antibody specifically binds IL-17.  
     
     
         7 . The method of  claim 4 , wherein the antibody is a humanized antibody.  
     
     
         8 . The method of  claim 4 , wherein the antibody is a single-chain antibody.  
     
     
         9 . The method of  claim 1 , wherein the IL-17 antagonist is administered one or more times per week.  
     
     
         10 . The method of  claim 1 , wherein the IL-17 antagonist is administered by subcutaneous injection.  
     
     
         11 . The method of  claim 1 , wherein the IL-17 antagonist is administered in combination with one or more compounds selected from the group consisting of non-steroidal anti-inflammatory drugs; analgesics; systemic steroids; antagonists of inflammatory cytokines; anti-inflammatory cytokines; chemotherapeutics; lipid-lowering drugs; blood pressure-regulating drugs; angiotensin-converting enzyme inhibitors and/or peroxisome proliferator-activated receptor ligands.